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substance of the wide range of problems, heterogeneous
populations, and differing circumstances faced by deci-
sion-makers has yet to be justified.
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OBJECTIVES:
 
 Clinical trials have demonstrated that
treatment can reduce the risk of osteoporosis-related
fractures in women over 50 years by 40%. The benefits
of treatment may be much lower due to lack of adherence
to treatment. Up to 20% of chronically ill patients fail to
initially fill their prescriptions, and 50% are noncompli-
ant after one year. We evaluated the feasibility of using a
database to estimate the relation between the occurrence
of fractures and adherence to osteoporosis medication in
actual practice.
METHODS: Major issues that were examined included:
whether there were sufficient subjects who received os-
teoporosis medication in the database; whether fracture
risk can be estimated in this population; how to deter-
mine whether a subject was covered for a given period
based on dispensing rather than prescribing data; when a
dispensing gap indicated non-persistence.
RESULTS: A community database of seven linked files
from Saskatchewan covering over 99% of its 1.1 million
residents was judged sufficiently large: 6,165 females older
than 45 were diagnosed in 2000 as ICD9 code 733, which
includes osteoporosis. Bisphosphonates were added to the
formulary in 1996. In 2000, 10,720 patients filled pre-
scriptions for the most widely used bisphosphonate and
33,585 filled prescriptions for conjugated estrogen. Physi-
cians or hospitals treated 12,765 females for fractures. Ad-
herence data were not available. A logical algorithm was
developed to determine persistence. It combined informa-
tion on minimally effective dose and maximum daily dos-
age with quantity, dose, dispensing date, drug type, and
tablet scoring, allowed for accumulation of medications
for later use, and corrected for hospitalizations.
CONCLUSIONS: The relation of fractures to adherence
with osteoporosis therapy can be studied through analy-
sis of this database using the algorithm.
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OBJECTIVES:
 
 To review and assess current measures of
caregiver burden in Alzheimer’s Disease (AD).
 
METHODS:
 
 A systematic search of MEDLINE, HEALTH-
STAR, and PUBMED databases was conducted to identify
all disease-specific and general caregiver-burden measures
used within the AD population. The accuracy and ultimate
value of a measure was assessed through three general psy-
chometric indices of performance: reliability; validity, and re-
sponsiveness. The evaluation of caregiver-burden instruments
along these psychometric properties were identified and com-
pared across measures.
RESULTS: A total of 62 articles were found to contain
background information or application of AD caregiver-
burden measures. Of these articles, ten measures were iden-
tified. Four were AD-specific and six were generic measures
used within the AD population. The available evidence of
each measure’s reliability, validity and responsiveness var-
ied. The Screen for Caregiver Burden (SCB) was the only
measure that reported reliability, construct and content va-
lidity, and responsiveness and performed well.
CONCLUSIONS: The lack of psychometric properties
reported in the majority of measures may limit the ability
to accurately assess caregiver burden and to evaluate
changes in response to interventions intended to lessen
this burden. Future validation studies of AD caregiver
measures will benefit by addressing these issues.
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OBJECTIVES: More than 40 EQ-5D have been evalu-
ated using a standardized time trade-off (TTO) protocol
in large-scale samples of the general public from the
United Kingdom (N  3395), Spain (N  979), and Ger-
many (N  339). This has created the first opportunity
to perform a large-scale comparison of TTO values be-
tween countries. This manuscript reports the mutual ef-
forts of several research groups within the EuroQol
Group to make such comparisons.
METHODS: Variation between the samples with respect to
background variables was controlled by multilevel analysis.
RESULTS: There are differences in TTO of health states:
the Spanish TTO values resemble the British, but the Ger-
man values are higher. The differences in TTO values are
larger than the small differences found in similar interna-
tional comparisons of VAS-based valuations. The differ-
ences found in the TTO can be explained in part by dif-
ferences in the distribution of background variables.
These results suggest that health is valued differently by
the three populations when measured using TTO, al-
though the differences are small. The differences found
seem to be driven by differences in the proportion and
the magnitude of negative health-state valuations. These
